Robert W. Baird initiated coverage on Astrana Health with a new price target
$ASTH
Professional Services
Consumer Discretionary
Robert W. Baird initiated coverage of Astrana Health with a rating of Outperform and set a new price target of $54.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2025 | $28.00 | Buy | Needham |
| 4/1/2025 | $36.00 | Equal Weight | Barclays |
| 10/14/2024 | $66.00 | Buy | TD Cowen |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | |
| 7/11/2024 | $44.00 → $50.00 | Hold → Buy | Truist |
| 5/30/2024 | $54.00 | Outperform | Robert W. Baird |
ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.
ALHAMBRA, Calif., Jan. 6, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership is participating in the J.P. Morgan 2026 Healthcare Conference, being held in San Francisco, on Monday, January 12, 2026, including a presentation at 5:15pm PT. The webcast link and related presentation materials will be available in the "IR Calendar" section of the Company's website: https://ir.astranahealth.com/news-events/ir-calendar.
Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (
Needham initiated coverage of Astrana Health with a rating of Buy and set a new price target of $28.00
Barclays initiated coverage of Astrana Health with a rating of Equal Weight and set a new price target of $36.00
TD Cowen initiated coverage of Astrana Health with a rating of Buy and set a new price target of $66.00
4 - Astrana Health, Inc. (0001083446) (Issuer)
4 - Astrana Health, Inc. (0001083446) (Issuer)
4 - Astrana Health, Inc. (0001083446) (Issuer)
SCHEDULE 13G/A - Astrana Health, Inc. (0001083446) (Subject)
8-K - Astrana Health, Inc. (0001083446) (Filer)
D - Astrana Health, Inc. (0001083446) (Filer)
ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.
Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (
ALHAMBRA, Calif., Oct. 15, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the third quarter ended September 30, 2025, after the close of the stock market on Thursday, November 6, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.